华东医药(000963) - 2016 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2016 was ¥6,165,697,645.94, representing an increase of 18.31% compared to ¥5,211,442,500.53 in the same period last year[8] - The net profit attributable to shareholders was ¥434,837,683.12, up 26.41% from ¥343,981,570.14 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥425,161,251.90, reflecting a 24.09% increase from ¥342,623,787.35 in the previous year[8] - The basic earnings per share increased to ¥0.9277, a rise of 17.06% compared to ¥0.7925 in the same period last year[8] Assets and Shareholder Equity - The total assets at the end of the reporting period were ¥13,531,454,495.49, an increase of 18.52% from ¥11,417,177,804.02 at the end of the previous year[8] - The net assets attributable to shareholders reached ¥6,874,342,663.86, showing a significant increase of 131.38% from ¥2,971,056,992.71 at the end of the previous year[8] Cash Flow and Operating Activities - The net cash flow from operating activities was negative at -¥619,505,186.12, a decline of 77.82% compared to -¥348,393,881.38 in the same period last year[8] - Cash flow from operating activities showed a net outflow of ¥619,505,186.12, a 77.82% increase in outflow compared to the previous period[17] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,942[12] - The largest shareholder, China Yuanda Group Co., Ltd., held 41.77% of the shares, amounting to 203,038,377 shares[12] Liabilities and Borrowings - Short-term borrowings decreased by 74.52% to ¥615,076,953.29 as funds from a private placement were used to repay short-term debts[16] Capital and Reserves - The capital reserve surged by 17,256.08% to ¥3,436,248,298.06, primarily from the premium of the private placement of 51,998,217 shares[16] Operating Expenses - Operating expenses rose by 38.92% to ¥177,711,266.80, attributed to increased R&D investment and expanded business operations[17] Receivables - Accounts receivable increased by 31.67% to ¥4,789,210,469.77 due to expanded business scale and increased sales[16] - Other receivables increased by 84.58% to ¥67,971,778.58, mainly due to an increase in receivable temporary payments[16] Financial Expenses - Financial expenses decreased by 48.52% to ¥25,692,697.75 due to reduced bank borrowings and interest expenses[17] Non-Operating Income - The company reported a significant increase in non-operating income by 317.45% to ¥15,447,472.02, primarily from government subsidies[17] - The company has no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[23]